All In Biotech

Drug Trial Radar · NCT06212076

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

A Phase I/II, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Characteristics and Initial Anti-tumor Activity of IPG1094 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 11, 2024

Primary completion

Jul 9, 2027

Study completion Jul 9, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and initial anti-tumor activity of IPG1094 in patients with advanced solid tumors. The study will be conducted in two parts: dose escalation phase (Part A) and expansion phase (Part B).

Conditions

  • Solid Tumor

Interventions

  • IPG1094Drug

    IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary endpointTime frame: Up to 6 months
  2. Primary endpointTime frame: Up to 2 months
  3. Primary endpointTime frame: Up to 3 months
  4. Primary endpointTime frame: Up to 8 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai GoBroad Cancer Hospital China Pharmaceutical University

    Shanghai, China · Recruiting

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.